Neurosurgery

ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint® 2.0 Software in Europe

Medicine, Clinical medicine, Medical specialties, Neurosurgery, Computer-assisted surgery, Biopsy, Stereotactic surgery, Surgical oncology, Magnetic resonance imaging

Thursday, January 14, 2021 - 9:05pm

The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain.

Key Points:

The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain.
ClearPoint offers a stereotactic system based on MRI localization with an MRI compatible frame.
We were delighted to support the talented team at Rigshospitalet during the first European procedure with our latest ClearPoint System, commented Matt Rabon, Clinical and Business Development Manager, EMEA.
Expanding into Europe fulfills our strategic mission to become the premier global therapy delivery partner in the Neuro space.

Marizyme Announces Approval for DuraGraft® in India

Neurosurgery, Vascular bypass

Thursday, January 14, 2021 - 12:33pm

India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.Currently, DuraGraft is approved in the EU and seven additional countries with more world-wide approvals pending.

Key Points:

India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.Currently, DuraGraft is approved in the EU and seven additional countries with more world-wide approvals pending.
Dr. Neil Campbell, Marizyme, Inc. President and CEO, said, "We are excited to receive this approval in India and to be working with Regency Lifesciences to bring the healthcare professionals and patients of India this first in class product.
India joins a growing list of countries that will form the basis of our commercial efforts in 2021 for DuraGraft."
Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com .

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Angiology, Medical specialties, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Stroke, Carotid ultrasonography, Carotid stenting

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points:

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points:

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

New Study Presents Impressive Results of Nexstim SmartFocus® nTMS Language Mapping

Brain tumor, Neurosurgery, Eloquence

Wednesday, January 13, 2021 - 11:00am

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a new study published in Cancers in January presents impressive results of nTMS language mapping in a large amount of patients.

Key Points:

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a new study published in Cancers in January presents impressive results of nTMS language mapping in a large amount of patients.
The study Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent GliomasA Large Scale Comparative Cohort Study Using a New Classification for Language Eloquence , using Nexstims NBS System with SmartFocus nTMS, was published by a neurosurgical team at Technical University of Munich (TUM) in Germany.
Nexstim SmartFocus nTMS pre-operative language mapping was performed on all these patients.
This distinguished study shows how Nexstims SmartFocus nTMS mapping can help to get very high gross total resection rates in language eloquent brain tumour surgeries without jeopardizing patients language function.

Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval

Medical specialties, Vascular diseases, Gross pathology, Branches of biology, Neurosurgery, Clinical medicine, Aneurysm, Bifurcation, Cerebrovascular diseases, Flow diverter, Interventional radiology

Tuesday, January 12, 2021 - 12:00pm

The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.

Key Points:

The WEB System is a unique, single-device treatment solution for wide neck bifurcation aneurysms in a new category of devices called intrasaccular flow disruptors.
When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.
"The excellent clinical results we can achieve with intrasaccular flow disruption technology has changed the way we approach the treatment of wide neck bifurcation aneurysms, and the WEB 17 System expands upon that.
When placed inside the aneurysm sac, the WEB device's proprietary microbraid technology bridges the aneurysm neck, disrupting blood flow, and creates a scaffold for long-lasting treatment.

Orthopedic Spine Surgeon Dr. Praveen Kadimcherla with Atlantic Spine Center explains why PT may help spine conditions and offers tips on what to expect

Medical specialties, Surgery, Surgical specialties, Medicine, Orthopedic surgery, Neurosurgery, National Center for Spinal Disorders, Minimally invasive spine surgery

Friday, January 8, 2021 - 3:00pm

If your doctor suggests this very helpful approach for acute or lingering back pain, it's smart to follow through, according to Praveen Kadimcherla, MD, an orthopedic spine surgeon at Atlantic Spine Center.

Key Points:

If your doctor suggests this very helpful approach for acute or lingering back pain, it's smart to follow through, according to Praveen Kadimcherla, MD, an orthopedic spine surgeon at Atlantic Spine Center.
"Most back pain responds to exercises and other treatments done under the guidance of a physical therapist," explains Dr. Kadimcherla, who is fellowship-trained in orthopedic and spine neurosurgery.
Atlantic Spine Center is a nationally recognized leader for endoscopic spine surgery with several locations in NJ and NYC.
http://www.atlanticspinecenter.com , http://www.atlanticspinecenter.nyc
Praveen Kadimcherla, MD, is a board-certified orthopedic spine surgeon at Atlantic Spine Center.

Monteris Medical Announces Health Care Service Corporation Policy Coverage for its NeuroBlate® System Laser Interstitial Thermotherapy for Brain Tumors and Epilepsy

Medicine, Clinical medicine, Medical specialties, Radiology, Ablation, Brain tumor, Neurosurgery, Magnetic resonance imaging, Interventional radiology, Ablative brain surgery, Interventional oncology

Wednesday, January 6, 2021 - 3:00pm

This update follows a similar policy decision by Blue Cross Blue Shield of North Carolina, which also provides coverage of MRI-guided laser ablation for patients with brain tumors and epilepsy.

Key Points:

This update follows a similar policy decision by Blue Cross Blue Shield of North Carolina, which also provides coverage of MRI-guided laser ablation for patients with brain tumors and epilepsy.
Many patients with brain tumors face situations in which traditional open brain surgery is neither possible, nor the preferred approach.
Monteris Medical's NeuroBlate laser ablation system is a tool used to destroy targeted tissue in the brain and provides a minimally invasive alternative for these patients and their physicians.
The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy.

CONMED Corporation to Present at the J.P. Morgan Virtual Healthcare Conference

Medical Supplies, Health, Medical devices, Hospitals, Surgery, Other Health, Cardiology, Health, Medicine, Surgeon, Residency, Neurosurgery

Tuesday, January 5, 2021 - 9:05pm

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President & Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 10:00 a.m.

Key Points:

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President & Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 10:00 a.m.
A live webcast of the presentation will be accessible through the Investors section of the Companys website at www.conmed.com and will be available for replay following the event.
CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures.
The Companys products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology.

Inspired Spine Study Demonstrates Effective Treatment of Spinal Stenosis without Laminectomy

Medical specialties, Surgery, Clinical medicine, Geriatrics, Spinal cord disorders, Lumbar spinal stenosis, Spinal fusion, Spinal stenosis, Neurosurgery, Vertebral column, Instrumented posterior lumbar interbody fusion, Failed back syndrome

Tuesday, December 22, 2020 - 6:34pm

BURNSVILLE, Minn., Dec. 22, 2020 /PRNewswire/ --Inspired Spine has released an innovative study on the effectiveness of the Physiologic decompression of Lumbar Spinal Stenosis through anatomic restoration using Trans-Kambin Oblique Lateral Posterior Lumbar Interbody Fusion (OLLIF) for the treatment of Spinal Stenosis.

Key Points:

BURNSVILLE, Minn., Dec. 22, 2020 /PRNewswire/ --Inspired Spine has released an innovative study on the effectiveness of the Physiologic decompression of Lumbar Spinal Stenosis through anatomic restoration using Trans-Kambin Oblique Lateral Posterior Lumbar Interbody Fusion (OLLIF) for the treatment of Spinal Stenosis.
Lumbar Spinal Stenosis (LSS) is one of the most common indications for spinal surgery.
Inspired Spine is a Minnesota based, innovative total spine Health Company that offers procedures that optimize the way lumbar fusions are performed.
To date, Inspired Spine Surgeons have performed over 1500 OLLIF procedures to successfully treat many lumbar spine conditions.